F-Prime Capital

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery, particularly in underserved populations that have been historically underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample-to-bioinformatics platform, utilizing advanced algorithms and innovative analyses to enhance genomic discovery. By identifying patients at risk for severe multi-inflammatory syndromes and infections, Galatea Bio aims to develop new tests, treatments, and cures that can significantly improve healthcare outcomes for diverse populations.

Laurus Bio specializes in precision fermentation, providing expertise to clients involved in microbial fermentation-based manufacturing and product development. The company focuses on the production of animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements. Their offerings cater to various sectors, including cultured meat, biologics, vaccine development, and regenerative medicine. By developing novel non-animal origin proteins and media components, Laurus Bio aims to enhance safety, consistency, and traceability in the pharmaceutical and bio-manufacturing industries, enabling clients to create greener and more sustainable healthcare products.

Based on our deep science and focused on patients in need.

Shift Bioscience is focused on using advanced simulation techniques to address the challenges of aging and age-related diseases. The company has developed a high-throughput aging biomarker that facilitates the identification of rejuvenation gene factors through AI-driven cell simulations. By employing deep learning technology, Shift tests extensive gene combinations to discover potential drugs that can reverse aging effects and repair mitochondrial genes. The ultimate goal is to create a single family of drugs capable of treating various diseases associated with aging, thereby promoting sustained health into old age through accessible prescriptions.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, specializing in the development of innovative platforms for the analysis of liquid and tissue biopsies. Founded in 2009, the company focuses on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs), which are critical for advancing precision medicine in oncology and cardiovascular disease. RareCyte's AccuCyte system offers an open platform that allows for the unbiased discovery and isolation of these rare cells from whole blood. The company provides a comprehensive suite of products, including sample preparation systems, staining kits, automated microscopy instruments, and imaging systems, which are utilized in various applications such as liquid biopsies, single-cell retrieval, and multi-parameter tissue analysis. By equipping researchers and medical professionals with advanced tools, RareCyte aims to enhance clinical research and foster the development of targeted therapies.

Engrail Therapeutics, Inc. is dedicated to developing and commercializing neuro drugs aimed at treating diseases of the nervous system. Founded in 2019 and based in San Diego, California, the company focuses on creating transformative medicines to alleviate the significant burden of such conditions. One of its key products is ENX-101, a preclinical compound designed to modulate a receptor for GABA, a critical neurotransmitter in the brain. Engrail Therapeutics combines biological insights with clinically meaningful solutions to advance its portfolio of therapies, utilizing a flexible transaction model to efficiently progress its drug candidates from development to commercialization.

Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.

PlasmaGen Biosciences Pvt. Ltd. is an Indian bio-pharmaceutical company based in Bengaluru, specializing in the manufacture of plasma-derived products and therapies. Established in 2010, the company develops a range of plasma protein therapies, including PlasmaGlob and AlbuMax, which are Normal Human Immunoglobulin formulations for intravenous use. Their product portfolio also includes PlasmaRho-D I.V. for Rho (D) immunization, PlasmaRAB for rabies post-exposure prophylaxis, and PlasmaHep for various hepatitis B-related indications. Additionally, PlasmaGen offers VerBumin for conditions such as hypovolemic shock and plasma exchange dialysis. The company serves a diverse clientele, including clinicians, medical practitioners, corporate hospitals, and government institutions, positioning itself as a key provider of plasma products across various medical fields, including hematology, oncology, and immunology.

Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.

T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

BenchSci is a developer of a research intelligence platform that leverages advanced artificial intelligence and machine learning to enhance biomedical discoveries. By translating both closed and open-access data into actionable recommendations, BenchSci enables researchers to optimize experiments, particularly in the area of antibody extraction. This innovative approach allows scientists to conduct more successful experiments efficiently, minimizing resource waste and accelerating drug discovery. The company's technology is utilized by pharmaceutical companies and over 4,300 research centers globally, underscoring its significant impact on the scientific community. BenchSci is backed by notable investors, including F-Prime, Gradient Ventures, and Inovia Capital.

Enzene Biosciences is a biotechnology company focused on providing affordable medicines through the development of biosimilars. The company employs advanced technologies, analytics, and a state-of-the-art manufacturing facility to enhance the efficiency of its operations. Enzene specializes in cloning, process development, and novel formulation development, which enables clients to leverage innovative solutions in commercial microbial manufacturing. By fostering strategic global alliances, Enzene aims to broaden the reach of its disruptive technologies and improve healthcare outcomes worldwide. The company is recognized for its strong workplace culture, making it an attractive employer in the biotech sector.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Elucidata Corporation, founded in 2015 and headquartered in New Delhi, India, specializes in accelerating drug discovery through its proprietary SaaS platform, Polly. This platform transforms drug discovery by delivering machine learning-ready biomedical molecular data, supported by a vast repository of over 230,000 multi-omic datasets, with more than 50,000 datasets added monthly. Polly curates this data semi-automatically, enabling data-driven drug discovery teams to integrate proprietary and public biomedical data for machine learning applications. By adhering to the FAIR guidelines, Polly's Data Lakes provide exclusive access to curated multi-omics data, facilitating faster identification of therapeutic assets with a higher likelihood of clinical success. The platform has proven instrumental in detecting validated drug targets across various fields, including immunology, oncology, and metabolomic disorders. Elucidata collaborates with leading organizations such as Pfizer, Agios Pharmaceuticals, and Genentech, as well as over 35 research partners from prominent biopharma companies and research institutions, enhancing decision-making processes in drug research and development.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

Peptone Ltd is a London-based company that specializes in developing artificial intelligence solutions aimed at addressing protein development challenges within the biotechnology, biopharmaceutical, and life sciences sectors. Established in 2016, Peptone focuses on the discovery of novel therapeutics, particularly targeting intrinsically disordered proteins. The company offers a range of services, including antibody design and optimization, a comprehensive protein database, and automated thermos-stability engineering. Its proprietary platform, CassandraAI, facilitates in silico protein engineering, enhancing the efficiency of protein development processes. Peptone's advanced protein engineering system addresses complex tasks such as anomaly detection and risk assessment, enabling clients to identify optimal strategies for resolving potential failures. This capability allows users to select suitable commercial partners to produce high-quality molecules more rapidly and cost-effectively than traditional methods employed in the pharmaceutical industry.

Proof Diagnostics is a life sciences company focused on developing diagnostic tools and therapeutic applications. It specializes in creating rapid diagnostic tests, including those for detecting infectious diseases such as coronavirus. The company offers diagnostic kits that enable medical professionals to test patients efficiently, enhancing the ability to identify infections quickly. Additionally, Proof Diagnostics is working on a smart, portable system aimed at improving the detection of various infectious diseases, thereby contributing to advancements in public health and disease management.

K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery, particularly in underserved populations that have been historically underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample-to-bioinformatics platform, utilizing advanced algorithms and innovative analyses to enhance genomic discovery. By identifying patients at risk for severe multi-inflammatory syndromes and infections, Galatea Bio aims to develop new tests, treatments, and cures that can significantly improve healthcare outcomes for diverse populations.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, specializing in the development of innovative platforms for the analysis of liquid and tissue biopsies. Founded in 2009, the company focuses on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs), which are critical for advancing precision medicine in oncology and cardiovascular disease. RareCyte's AccuCyte system offers an open platform that allows for the unbiased discovery and isolation of these rare cells from whole blood. The company provides a comprehensive suite of products, including sample preparation systems, staining kits, automated microscopy instruments, and imaging systems, which are utilized in various applications such as liquid biopsies, single-cell retrieval, and multi-parameter tissue analysis. By equipping researchers and medical professionals with advanced tools, RareCyte aims to enhance clinical research and foster the development of targeted therapies.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of targeted therapies for rare disorders. Based in Wayne, Pennsylvania, the company primarily addresses conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevus sebaceous. NFlection specializes in treatments that target the Ras/Raf/MEK/ERK signaling pathway, which is often aberrantly activated in these disorders. One of its notable developments includes a soft mitogen-activated protein kinase (MEK) formulated as a cosmetically elegant gel for topical application, allowing for localized treatment while minimizing systemic side effects typically associated with orally administered MEK inhibitors. Founded in 2014, NFlection Therapeutics aims to improve patient outcomes through innovative therapeutic solutions.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.

Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

BenchSci is a developer of a research intelligence platform that leverages advanced artificial intelligence and machine learning to enhance biomedical discoveries. By translating both closed and open-access data into actionable recommendations, BenchSci enables researchers to optimize experiments, particularly in the area of antibody extraction. This innovative approach allows scientists to conduct more successful experiments efficiently, minimizing resource waste and accelerating drug discovery. The company's technology is utilized by pharmaceutical companies and over 4,300 research centers globally, underscoring its significant impact on the scientific community. BenchSci is backed by notable investors, including F-Prime, Gradient Ventures, and Inovia Capital.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

Sironax is a clinical-stage biotechnology company based in Beijing, China, founded in 2017. The company focuses on developing innovative products and treatments for age-related degenerative diseases, concentrating on mechanisms such as regulated cell death, neuroprotective pathways, and neuroinflammation. By researching apoptosis and other cell death pathways, Sironax aims to create advanced pharmaceuticals that can improve the lives of patients suffering from these conditions. Their goal is to transform the treatment landscape for age-related degenerative diseases, benefiting millions of patients and their families globally.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, that develops a community-owned platform for genomic and medical research. The company's primary offering, LunaDNA, serves as a knowledge database where individuals can share their health and DNA data to contribute to health research and drive medical discoveries. This platform is designed to benefit both non-profit and for-profit health research projects, facilitating collaboration among pharmaceutical, insurance, and healthcare IT companies. In addition to advancing medical research, LunaPBC allows its members to share in the financial benefits derived from medical breakthroughs, promoting a model of shared community ownership.

LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Genomics PLC, established in 2014 and headquartered in Oxford, UK, specializes in developing algorithms and software solutions that harness the power of genomics. The company focuses on cancer, microbes, and rare diseases, offering solutions that transform healthcare provisions for governments and providers, de-risk drug development for pharmaceutical clients, enhance diagnoses and treatment options for clinicians, and ensure accurate result processing for research labs and genome analysts. By applying advanced analytics to massive genomic and phenotypic datasets, Genomics PLC aims to lead the genomic transformation of healthcare, revealing the human wiring diagram and setting standards for genomic data utilization.

Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.

Benchling, Inc. is a cloud-based informatics company that provides a comprehensive platform tailored for life sciences research and development. Its flagship offering allows scientists to design, share, and document experiments through an integrated interface, enhancing collaboration and efficiency. The platform includes Benchling Insights, which enables users to query and visualize structured data, and a Bioregistry system for managing biological entity registrations and inventory such as plasmids and cell strains. Benchling's solutions support a variety of applications, including antibodies, cell therapy, gene therapy, and vaccines, catering to the needs of scientists in biotech, pharmaceutical, academic, and government sectors. Founded in 2012 and headquartered in San Francisco, Benchling aims to streamline the research process from discovery to bioprocessing, facilitating critical R&D decisions with its unified software suite.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Indalo Therapeutics is a preclinical-stage biotechnology company focused on developing innovative therapies for patients afflicted by fibrotic diseases. Founded on significant scientific advancements, the company leverages deep insights into the molecular mechanisms that drive abnormal scarring. By assembling a skilled team of pharmaceutical scientists and industry executives, Indalo aims to address critical unmet medical needs in the field of fibrosis. Its therapeutic approach seeks to not only halt but also potentially reverse the progression of fibrotic conditions, ultimately improving the quality of life for affected individuals.

PlasmaGen Biosciences Pvt. Ltd. is an Indian bio-pharmaceutical company based in Bengaluru, specializing in the manufacture of plasma-derived products and therapies. Established in 2010, the company develops a range of plasma protein therapies, including PlasmaGlob and AlbuMax, which are Normal Human Immunoglobulin formulations for intravenous use. Their product portfolio also includes PlasmaRho-D I.V. for Rho (D) immunization, PlasmaRAB for rabies post-exposure prophylaxis, and PlasmaHep for various hepatitis B-related indications. Additionally, PlasmaGen offers VerBumin for conditions such as hypovolemic shock and plasma exchange dialysis. The company serves a diverse clientele, including clinicians, medical practitioners, corporate hospitals, and government institutions, positioning itself as a key provider of plasma products across various medical fields, including hematology, oncology, and immunology.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment specifically designed for cancer and cell biology research. The company offers advanced flow cytometers, including the Cytek Aurora and Cytek Northern Lights, as well as the DxP Athena system, which utilizes proprietary technology to enhance the detection of dim populations in a multicolor format. In addition, Cytek provides the QbSure quality control program to ensure the optimal performance of its cytometers and a range of cFluor reagents tailored for use in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence internationally with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company was previously known as Cytoville, Inc. before rebranding in August 2015.

Core Diagnostics Private Limited, established in 2012 and located in Gurugram, India, is a clinical laboratory specializing in advanced diagnostic solutions aimed at disease stratification and therapy selection. The company emphasizes the use of next-generation diagnostic techniques to enhance healthcare outcomes, striving to provide comprehensive and high-quality testing services. With a commitment to innovation, Core Diagnostics aims to be a leading provider of sophisticated diagnostic solutions in India, catering to the growing demand for precision medicine.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, that specializes in cellular engineering and genome editing solutions using CRISPR technology. Incorporated in 2011, the company has developed a CRISPR-Cas gene editing platform that allows precise modifications to DNA, which is applicable across various fields including human and animal therapeutics, agricultural biotechnology, and industrial biotech. Caribou's innovative approach aims to create transformative therapies, particularly in the development of allogeneic CAR-T and CAR-NK cell therapies, targeting serious diseases. The company focuses on advancing its pipeline of next-generation genome-edited cell therapies while also contributing to basic and applied biological research.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment specifically designed for cancer and cell biology research. The company offers advanced flow cytometers, including the Cytek Aurora and Cytek Northern Lights, as well as the DxP Athena system, which utilizes proprietary technology to enhance the detection of dim populations in a multicolor format. In addition, Cytek provides the QbSure quality control program to ensure the optimal performance of its cytometers and a range of cFluor reagents tailored for use in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence internationally with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company was previously known as Cytoville, Inc. before rebranding in August 2015.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Regenxbio Inc. is a clinical-stage biotechnology company focused on developing gene therapy products to address genetic disorders and enable cells to produce therapeutic proteins and antibodies. The company leverages its proprietary NAV Technology Platform, which utilizes adeno-associated virus vectors for gene delivery. Regenxbio's lead product candidate, RGX-314, is under investigation in a Phase I/IIa clinical trial for wet age-related macular degeneration. Other notable product candidates include RGX-121 and RGX-111, which are in clinical trials for mucopolysaccharidosis type II and I, respectively, as well as RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Additionally, Regenxbio licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and collaborates with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health infections, particularly bacterial vaginosis (BV). Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in the development of its lead product, Solosec (secnidazole), a next-generation 5-nitroimidazole antibiotic designed for a convenient one-dose treatment. This drug offers enhanced pharmacokinetic properties that improve efficacy and tolerability for patients. Symbiomix is supported by prominent healthcare venture capital firms and aims to address the unmet therapeutic needs in the field of gynecologic infections. Since October 2017, it has operated as a subsidiary of Lupin Inc.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, that specializes in cellular engineering and genome editing solutions using CRISPR technology. Incorporated in 2011, the company has developed a CRISPR-Cas gene editing platform that allows precise modifications to DNA, which is applicable across various fields including human and animal therapeutics, agricultural biotechnology, and industrial biotech. Caribou's innovative approach aims to create transformative therapies, particularly in the development of allogeneic CAR-T and CAR-NK cell therapies, targeting serious diseases. The company focuses on advancing its pipeline of next-generation genome-edited cell therapies while also contributing to basic and applied biological research.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

Regenxbio Inc. is a clinical-stage biotechnology company focused on developing gene therapy products to address genetic disorders and enable cells to produce therapeutic proteins and antibodies. The company leverages its proprietary NAV Technology Platform, which utilizes adeno-associated virus vectors for gene delivery. Regenxbio's lead product candidate, RGX-314, is under investigation in a Phase I/IIa clinical trial for wet age-related macular degeneration. Other notable product candidates include RGX-121 and RGX-111, which are in clinical trials for mucopolysaccharidosis type II and I, respectively, as well as RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Additionally, Regenxbio licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and collaborates with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment specifically designed for cancer and cell biology research. The company offers advanced flow cytometers, including the Cytek Aurora and Cytek Northern Lights, as well as the DxP Athena system, which utilizes proprietary technology to enhance the detection of dim populations in a multicolor format. In addition, Cytek provides the QbSure quality control program to ensure the optimal performance of its cytometers and a range of cFluor reagents tailored for use in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence internationally with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company was previously known as Cytoville, Inc. before rebranding in August 2015.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health infections, particularly bacterial vaginosis (BV). Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in the development of its lead product, Solosec (secnidazole), a next-generation 5-nitroimidazole antibiotic designed for a convenient one-dose treatment. This drug offers enhanced pharmacokinetic properties that improve efficacy and tolerability for patients. Symbiomix is supported by prominent healthcare venture capital firms and aims to address the unmet therapeutic needs in the field of gynecologic infections. Since October 2017, it has operated as a subsidiary of Lupin Inc.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.

BIKAM Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in developing novel therapeutics aimed at treating retinal degenerative diseases, particularly focusing on conditions such as retinitis pigmentosa and dry age-related macular degeneration. BIKAM's research centers on small molecule, non-retinoid pharmacological chaperones designed to address issues related to misfolded proteins within the retina. Their lead product is an orally active pharmacological chaperone that targets misfolded rod opsin, which is implicated in retinitis pigmentosa, helping to correct its trafficking to the rod cell surface and outer segment. Through its innovative approach, BIKAM Pharmaceuticals strives to provide new treatment options for patients suffering from these serious retinal conditions.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.